Erenumab
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine
Trial Timeline
Feb 8, 2018 → Jan 13, 2020
NCT ID
NCT03333109About Erenumab
Erenumab is a phase 3 stage product being developed by Novartis for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03333109. Target conditions include Episodic Migraine.
What happened to similar drugs?
3 of 15 similar drugs in Episodic Migraine were approved
Approved (3) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04084314 | Approved | Completed |
| NCT03867201 | Phase 3 | Completed |
| NCT03333109 | Phase 3 | Completed |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 44 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| BOTOX + Placebo | AbbVie | Phase 3 | 32 |
| Atogepant 60 mg | AbbVie | Phase 3 | 40 |
| Atogepant + Ubrogepant | AbbVie | Approved | 43 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 47 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 43 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 40 |
| Placebo + AMG 301 | Amgen | Phase 2 | 35 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 29 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 41 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 39 |
| Methylprednisolone | Brain Biotech | Approved | 33 |